« Back
Home /
Danoprevir

Danoprevir

Item no.	S1183-50
Manufacturer	Selleckchem
CASRN	850876-88-9
Amount	50 mg
Quantity options	10 mg 1 g 10 g 10 mM/1 ml 2 mg 200 mg 5 mg 50 mg 5 g
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Smiles	CC(C)(C)OC(=O)NC1CCCCCC=CC2CC2(NC(=O)C3CC(CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	ITMN-191,RG7227
Similar products	Danoprevir
Available
Storage Conditions	2 years -80 in solvent
Molecular Weight	731, 83
Administration	Oral gavage
Animal Models	Sprague-Dawley rats, Cynomolgus monkeys
Cell lines	Huh7 cells harboring HCV replicon
Clinical Trials	Danoprevir, associated with RO5024048, is currently under investigation in Phase II clinical trials in genotype 1 chronic hepatitis C.
Concentrations	5 pM - 100 nM
Dosages	30 mg/kg
Formulation	Dissolved in water. 6 mg/mL for rats and 3 mg/mL for monkeys
IC50	0.2-3.5 nM [1], 0.2-3.5 nM [1], 0.2-3.5 nM [1], 0.2-3.5 nM [1], 0.2-3.5 nM [1], 0.2-3.5 nM [1]
In vitro	Danoprevir (0.29 nM) inhibits the reference genotype 1 NS3/4A protease half-maximally, but a high dose of Danoprevir (10 uM) shows no appreciably inhibition in a panel of 79 proteases, ion channels, transporters, and cell surface receptors. Danoprevir remains bound to and inhibits NS3/4A for more than 5 hours after its initial association. Danoprevir (45 nM) eliminates a patient-derived HCV genotype 1b replicon from hepatocyte-derived Huh7 cells with an EC50 of 1.8 nM. [1] In HCV subgenomic replicon cell lines containing the individual mutations, V36M, R109K, and V170A substitutions confer little or no resistance to Danoprevir, but the R155K substitution confers a high level (62-fold increase) of resistance to Danoprevir. [2] In Huh7.5 cells transfected with chimeric recombinant virus, Danoprevir shows antiviral inhibition effects against HCV genotypes 1, 4 and 6 with IC50 of 2-3 nM, which are >100-fold lower than genotypes 2/3/5 (280-750 nM). [3]
In vivo	Danoprevir (30 mg/kg) administered to rats or monkeys shows that its concentrations in liver 12 hours after dosing exceed the Danoprevir concentration required to eliminate replicon RNA from cells. [1]
Incubation Time	48 hours
Kinase Assay	Continuous fluorescent resonance energy transfer (FRET) assay, The assay buffer contains 25 uM NS4A peptide, 50 mM Tris-HCl, pH 7.5, 15% (vol/vol) glycerol, 0.6 mM lauryldimethylamine N-oxide, 10 mM dithiothreitol, and 0.5 uM fluorescein/QXL520-labeled FRET substrate {Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2}. K2040 enzyme (50 pM) is added to initiate the reaction. Reactions are set up in black 96-well plates, and fluorescence data is collected. Control reactions lacking inhibitors and enzyme are included. Initial rates are calculated from the linear phase of the reaction (up to 1 hour) and are used to obtain IC50. Recovery of activity from preformed Danoprevir-NS3/4A complex is assessed by preincubating 10 nM NS3/4A with a two-fold excess of Danoprevir in 1x assay buffer for 15 min, followed by a rapid 200-fold dilution of the preformed complex into assay buffer containing substrate. A control reaction with the same final conditions without preincubation of NS3/4A and Danoprevir is initiated by the addition of enzyme to an otherwise-complete reaction mixture. Additional control reactions lack either Danoprevir or NS3. The progress of the reactions is followed over 5 hours.
Method	Serially diluted Danoprevir is added to Huh7 cells harboring the K2040 replicon 1 day after cell plating. For antiviral assays, after a 48-hour incubation, intracellular RNA is extracted, and the level of HCV replicon RNA is quantified by reverse transcription (RT)-PCR assay with the primers (5'-CACTCCCCTGTGAGGAACTACTG-3' and 5'-AGGCTGCACGACACTCATACT-3') and a probe (5'-6-FAM-CTTCACGCAGAAAGCGTCTAGCCATGG-MGBNFQ-3' using an ABI Prism 7900 sequence detection system. Here, FAM is 6-carboxyfluorescin and MGBNFQ is a molecular-groove binding non-fluorescence quencher specific to the HCV 5' untranslated region. Single-tube reactions are performed using the TaqMan Gold RT-PCR kit. Triplicate reactions for the RNA standards and samples are performed in 50 uL with 5 uL intracellular RNA (50 ng). RT is carried out at 48 C for 30 min followed by 10 min at 95 C. The PCR is run as follows: 15 seconds at 95 C and 1 min at 60 C for 40 cycles. Each RNA concentration is determined in triplicate. The absolute concentration of replicon RNA is calculated based on its signal relative to that of a standard curve generated by known concentrations of an in vitro-transcribed RNA corresponding to a genotype 1b 5' untranslated region. Replicon levels in the presence of Danoprevir are fitted to a four-parameter logistic function to obtain EC50.
Solubility (25C)	DMSO 144 mg/mL, Water <1 mg/mL, Ethanol 144 mg/mL
Information	Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
Chemical Name	2H-Isoindole-2-carboxylic acid, 4-fluoro-1, 3-dihydro-, (2R, 6S, 13aS, 14aR, 16aS)-14a-[[(cyclopropylsulfonyl)amino]carbonyl]-6-[[(1, 1-dimethylethoxy)carbonyl]amino]-1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13a, 14, 14a, 15, 16, 16a-hexadecahydro-5, 16-dioxocyclopropa[e]pyrrolo[1, 2-a][1, 4]diazacyclopentadecin-2-yl ester
Features	Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV).

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

S1183-50-datasheet.pdf

S1183-50-safety-datasheet.pdf